BioVie (BIVI) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
8 Jul, 2026Opening remarks and agenda
Meeting called to order by the Chairman, with board members and key executives in attendance virtually.
Independent public accountants and outside securities counsel also present.
Secretary appointed to record minutes and confirm formal meeting procedures.
Corporate governance
Record date for voting set as September 30, 2024, with 7,956,660 shares outstanding.
Notice of meeting and proxy materials mailed to shareholders on October 9, 2024.
Quorum established with over 60% of shares represented.
Overview of voting outcomes
Six directors elected for a one-year term by plurality of votes.
Auditor ratification approved with 93.2% of represented shares.
Say-On-Pay Proposal approved with 93.9% support.
Amendment to the 2019 Omnibus Equity Incentive Plan approved with 92.6% support.
Latest events from BioVie
- Biotech seeks up to $70M via share and warrant offering to fund R&D, facing high risk and dilution.BIVI
Registration filing31 Jul 2026 - Biotech seeks capital for late-stage neuro and liver drug programs amid ongoing losses and legal risks.BIVI
Registration filing17 Jul 2026 - Bezisterim targets neuroinflammation in early Parkinson's with a novel, patient-friendly trial design.BIVI
Status Update9 Jul 2026 - Biotech seeks to raise up to $300M for neuro and liver disease R&D via flexible securities offering.BIVI
Registration filing18 Jun 2026 - Imminent clinical data for Parkinson's and Long COVID could unlock major market opportunities.BIVI
Investor update2 Jun 2026 - Bezisterim and BIV201 show promising efficacy in neurodegenerative and liver disease trials.BIVI
Corporate presentation2 Jun 2026 - Bezisterim targets neuroinflammation and metabolic dysregulation to address Parkinson's progression.BIVI
KOL event14 May 2026 - Net loss widened to $5.3M for the quarter as R&D spending rose, with cash at $13.1M.BIVI
Q3 202611 May 2026 - Lead therapies show strong efficacy in neurodegeneration and ascites, with high commercial potential.BIVI
Corporate presentation23 Apr 2026